CCR5 is the chemokine co-receptor for R5-tropic human immunodeficiency virus type 1 (HIV-1) isolates most often associated with primary infection. We have developed an HIV-1 self-inactivating vector, CAD-R5, containing a CCR5 single-chain antibody (intrabody) gene, which when expressed in T-cell lines and primary CD4 + T cells disrupts CCR5 cell surface expression and provides protection from R5-tropic isolate exposure. Furthermore, CAD-R5 intrabody expression in primary CD4 + T cells supports significant growth and enrichment over time during HIV-1-pulsed dendritic cell-T-cell interactions. These results indicate that CCR5 intrabody-expressing CD4 + T cells are refractory against this highly efficient primary route of infection. CD34 + cells transduced with the CAD-R5 vector gave rise to CD4 + and CD8 + thymocytes in non-obese diabetic (NOD)/ severely combined-immunodeficient (SCID)-human thymus/ liver (hu thy/liv) mice, suggesting that CCR5 intrabody expression can be maintained throughout differentiation without obvious cellular effects. CD4 + T cells isolated from NOD/SCID-hu thy/liv mice were resistant to R5-tropic HIV-1 challenge demonstrating the maintenance of protection. Our findings demonstrate delivery of anti-HIV-1 activity through CCR5 intrabodies in primary CD4 + T cells and CD34 + cell-derived T-cell progeny. Thus, gene delivery strategies that provide a selective survival and growth advantage for T effector cells may provide a therapeutic benefit for HIV-1-infected individuals who have failed conventional therapies.
Introduction
A multiplicity of chemokine co-receptors have been shown to facilitate human immunodeficiency virus type 1 (HIV-1) entry in tissue culture; however, only CCR5 and CXCR4 (the X4-tropic HIV-1 co-receptor) have been convincingly demonstrated to be the relevant chemokine receptors in man. [1] [2] [3] [4] Although viral isolates utilizing CCR5 and CXCR4 for entry potentially could be transmitted from individual to individual, it appears that CCR5 using HIV-1 species are the predominant viruses transmitted. 5, 6 Moreover, susceptibility to viral infection and disease progression are correlated to cell surface CCR5 levels. For example, individuals with a 32 base pair (bp) homozygous deletion in their CCR5 gene (D32) lack functional CCR5 expression and are protected against infection. [7] [8] [9] [10] Individuals heterozygous for the D32 mutation have reduced levels of CCR5 and are delayed in their progression to AIDS by 1-2 years. 8 Additionally, mutations in the CCR5 promoter, such as the 59029 G/A polymorphism, reduce activity by 45% and also delay progression to AIDS by about 4 years. 11, 12 Finally, disruption of CCR5 expression does not appear to be critical for normal cell function, as individuals with these naturally occurring polymorphisms do not seem to be associated with any detrimental phenotype (see O'Brien and Moore 4 for a review). Therefore, intervention strategies aimed at altering CCR5 expression may be beneficial for cellular protection against HIV-1 infection and provide a clinical benefit.
Specific targeting of chemokine receptors utilizing intrakines, RNA interference (RNAi), intrabodies, or ribozymes by vector delivery have proved effective in tissue culture. [13] [14] [15] [16] However, these viral entry disruption strategies have shown varying levels of protection when the viral challenge dose is increased, thus providing the caution that therapeutic efficacy may be breached by high viral loads. [17] [18] [19] Recent studies have indicated that HIV-1 may be more effectively transmitted during antigen presentation between CD4 + T cells and HIV-1 exposed or infected dendritic cells (DCs), termed an infectious immunological synapse, thus providing a means for increased local viral levels. [20] [21] [22] [23] [24] As it may be impossible to protect all susceptible cells in an individual through gene delivery, the delivered protection must function to allow a limited number of primary T cells to survive, enrich, and function in the face of a robust, widespread HIV-1 infection mediated via free virus and cell-to-cell interaction.
Herein, we examined whether the HIV-1 derived selfinactivating (SIN) vector, CAD-R5, can deliver CCR5 intrabody genes to primary T and CD34
+ hematopoietic cells and whether the resulting intrabody expression in CD4 + T cells promoted a survival and growth advantage during HIV-1 challenge. The CCR5 intrabody is specific for the N-terminal extracellular domain of CCR5 and engineered with the Lys-Asp-Glu-Leu (KDEL) endoplasmic reticulum retention signal. 16, 25 We determined that expression of the CCR5 intrabody from the CAD-R5 vector resulted in almost complete disruption of CCR5 cell surface expression and protected both T-cell lines and primary CD4 + T cells from robust infection with free R5-tropic viruses. Furthermore, intrabody-expressing CD4 + T cells, obtained from non-obese diabetic/severely combined immunodeficient (NOD/SCID)-human thymus/liver (hu thy/liv) mice transplanted with CAD-R5-transduced CD34 + cells, were protected from high-titer R5-tropic HIV-1 challenge in tissue culture. Most importantly, intrabody-expressing primary CD4 + T cells have a selective survival and growth advantage during DC-mediated viral challenge.
Results
CCR5 intrabody-mediated disruption of CCR5 cell surface expression in THP-1 and primary CD4 + T cells
In our previous report, we demonstrated that a PM1 T-cell line expressing moderate levels of CCR5 intrabody from cells with multiple transgenes was protected from R5-tropic HIV-1 challenge generated by repeated transductions and drug selection. 16 If cellular modifications of chemokine receptors by gene delivery are to be effective for abrogating HIV-1 entry in primary CD4 + T cells, CCR5 intrabodies must function effectively when expressed from the gene delivery vehicle of choice at low vector copy number. To determine whether CCR5 intrabodies can provide protection to leukocytes, lentiviral vectors were developed that expressed the CCR5 intrabody gene, CAD-R5, and a control vector, CAD, which did not include the CCR5 intrabody gene ( Figure  1a) . To determine the efficacy of the CAD-R5 vector to alter CCR5 expression, we first evaluated CAD-R5 vector function in the THP-1 monocytic cell line, which is known to express CCR5 at moderate to high levels on the cell surface (Figure 1b) . 26 THP-1 cells were transduced at a low multiplicity of infection (MOI ¼ 1) to obtain a low vector copy number per cell. Two weeks after transduction, the mean fluorescence intensity (MFI) for CCR5 expression in the THP-1 CAD-R5 cell was decreased from an MFI of 27-6, an expression level similar to background levels obtained from the irrelevant (non-CCR5) isotype control antibody. These cells have been maintained in tissue culture for 12 weeks with little change in CCR5 or truncated nerve growth factor receptor (tNGFR) expression (data not shown). These findings show that CCR5 intrabody gene expression from a lentiviral vector decreases both the percentage of CCR5-positive cells and the overall amount of CCR5 available on the surface of each cell.
Next, we evaluated whether CCR5 intrabody gene expression from the CAD-R5 vector would alter CCR5 expression on the cell surface of primary CD4 + T cells. CD4 + T cells were transduced with CAD or CAD-R5 vectors, rested and reactivated to obtain maximum CCR5 expression levels. 27, 28 Consistent with our findings in THP-1 cells, CCR5 expression levels in CAD-R5 vectortransduced primary CD4 + T cells shifted from an MFI of 34 in the parental or control CAD vector-transduced cells to background MFI levels of 8, an expression level CCR5 intrabody-mediated protection and enrichment of T cells during HIV-1 infection CH Swan et al similar to background levels obtained from the irrelevant (non-CCR5) isotype control antibody (Figure 1c ). Lastly, this was a specific effect as CXCR4 expression levels were not altered in CAD-R5-positive CD4 + T cells ( Figure  1d ). When taken together, these results are consistent with the interpretation that the CAD-R5 vector significantly reduces CCR5 cell surface levels in primary CD4 + T cells.
CCR5 intrabody-expressing T-cell lines and primary CD4 + T cells are resistant to R5-tropic HIV-1 challenge
To determine if the CAD-R5 vector provided protection from R5-tropic HIV-1 challenge, PM1 T-cell lines were established by selection of tNGFR reporter-expressing CAD and CAD-R5 vector-transduced cells. The PM1 CAD and PM1 CAD-R5 lines, more than 99% positive for the tNGFR, were challenged with 1% irradiated R5-tropic NFN-SX-r-HSAS reporter-infected PM1 cells. The NFN-SX-r-HSAS reporter virus expresses mouse heat-stable antigen (mHSA) on the cell surface upon productive infection allowing real-time flow cytometry analysis of infected cells. 16, 29 Figure 2a presents the flow cytometry analysis 6 days after the mixture of the productively infected NFN-SX-r-HSAS cells with various PM1 T-cell populations. The productively infected parental PM1 line and CAD lines were readily identifiable as demonstrated by the right-shift of mHSA-positive cells. In contrast, the PM1 CAD-R5 line remained mHSA negative during challenge with R5-tropic chronically infected PM1 cells. To evaluate nonspecific protective effects of vector transduction and intrabody expression, the PM1 CAD and CAD-R5 lines were infected with the X4-tropic NL-r-HSAS mHSA-expressing reporter virus at an MOI of 0.1. The PM1 parental, CAD and CAD-R5 cell lines were mHSA positive following X4-tropic NL-r-HSAS infection. These findings demonstrate the specificity of the CCR5 intrabody for altering CCR5 expression and modifying R5-tropic infection and the absence of nonspecific HIV-1-blocking effects from vector transduction and/or CCR5 intrabody expression.
Given the higher amounts of CCR5 present on primary CD4 + T cells than PM1 T cells, we next evaluated whether CAD-R5 vector transduction and CCR5 intrabody expression provided protection from R5-tropic SF-162 viral challenge. Primary CD4 + T cells were transduced with the CAD or the CAD-R5 vector, enriched for tNGFR expression, cultured, reactivated after resting and then challenged with SF-162 at an MOI of 1. Culture supernatants were collected for p24 analysis on various days post-infection to determine HIV-1 production. The p24 results from two out of three representative experiments demonstrate that the CAD-R5-transduced T cells are resistant to HIV-1 infection and displayed a 50-to 60-fold reduction (1.5 log) of p24 as compared to the CAD vector and untransduced infected controls (Figure 2b) . The second experiment shown included untransduced control cells to confirm that cells transduced with the CAD vector were able to obtain similar levels of HIV-1 infection as non-transduced cells. To determine the specificity of CCR5 intrabody control and assess possible global changes in viral infection brought about by intrabody expression in primary CD4 + T cells, parental, CAD and CAD-R5 stably transduced cells were challenged with the X4-tropic viral isolate laboratory adapted isolates (LAI)/IIIB. As shown in Figure 2c , LAI enters and replicates equally well in parental, CAD and CAD-R5 stably transduced cells. Together, the findings from the PM1 and primary CD4 + T-cell HIV-1 challenge studies demonstrate the therapeutic efficacy of CAD-R5 delivery and specificity of CCR5 intrabody-mediated protection. + cells (80% tNGFR positive) were directly injected into the graft. Six weeks after reconstitution, the thy/liv grafts were harvested and analyzed for human thymocyte development. Table 1 presents the human CD4 + and CD8 + T-cell flow cytometry profile for the HLA-mismatched donor population for all three experimental groups, mock transduced, CAD and CAD-R5 as a percentage of total donor and NGFR-positive cells. Thymocytes from the CAD and CAD-R5 NOD/SCID-hu thy/liv mice (n ¼ 2) were positive for tNGFR reporter gene expression and both displayed significant levels of tNGFR expression (15-32%). All three groups displayed similar patterns of thymocyte sub-populations with a majority of the cells being CD4 + /CD8 + and a small percentage of CD4 + and CD8 + single positive cells. The CAD tNGFR-positive population displayed a slightly higher percentage of single positive CD4 and CD8 T cells as compared to the CAD-R5 tNGFR population. However, this trend is seen upon analysis of the whole HLA-mismatched population for the CAD and CAD-R5 groups. These finding suggest transduction, vector integration, CCR5 intrabody expression and/or CCR5 cell surface expression disruption did not have an overt affect on thymocyte development.
NOD

CCR5 intrabody-mediated protection from R5-tropic HIV-1 in primary thymocytes
As R5-tropic viral isolates are known to not replicate to high levels and cause pathology in SCID-hu thy/liv mice, 33 we utilized a tissue culture assay for evaluating CCR5 intrabody-mediated protection. 34, 35 To mimic functionally an in vivo setting where not all CD4 + T cells are protected during a viral infection, a mixture of unprotected (non-transduced) and CCR5 intrabody gene--positive thymic-derived cells were used. We reasoned + T-cell cultures were not infected (ÀHIV) or infected with LAI at an MOI of 0.1 (+HIV) and viral replication was determined at the times indicated by p24 evaluation. All CAD or CAD-R5 CD4 + T-cells cultures were composed of 498% tNGFR-expressing cells, see Materials and methods for additional information.
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In our viral challenge assays, differences were evident in the amount and duration of viral replication in cultures containing CAD-R5 intrabody-positive cells, as compared to cultures containing CAD and non-transduced control CD4 + T cells. As can be seen in Figure 3 , p24 levels in the CAD-R5 cultures increased above the uninfected control cultures until day 5 after which time p24 levels remained constant throughout the 17-day observation period, thus indicating that maximal viral infection had been reached by day 5. In contrast, the CAD and untransduced control cultures had increased and continued viral replication, and presumably viral spread, over the culture period as indicated by the increasing p24 levels. Moreover, by day 17, the increased viral replication in CAD and untransduced control cultures resulted in approximately threefold higher p24 levels as compared to the CAD-R5 cultures. After day 11 in untransduced control cultures, the p24 levels fell, presumably owing to loss of susceptible targets in culture as the result of cellular death.
Enrichment of the PM1 CD4 + T-cell line expressing the CCR5 intrabody upon R5-tropic HIV-1 infection
An underlying assumption for HIV-1 protective gene therapy of CD4 + T cells is that the cellular protection afforded by the delivered product will promote survival and enrichment over time in the face of an ongoing infection. 36, 37 Our previous findings using a neomycin PM1 cell line selected for high levels of CCR5 intrabody transgene integration demonstrated a 7-day survival advantage after R5-tropic viral exposure. 16, 25 To further investigate if CCR5 intrabody expression provides both survival and cell expansion, we established assays to determine if small numbers of PM1 CAD-R5-transduced cells have a selective survival and growth advantage during an ongoing HIV-1 infection.
PM1 T cells were transduced at a low MOI to achieve a transduction frequency of less than 20% tNGFR-expressing cells. A low MOI was used to reduce the probability of increased vector copy number per cell, 38 thereby allowing a determination of therapeutic efficacy at low vector copy number. PM1 T-cell cultures were established with 15% CAD-transduced and 5% CAD-R5-transduced PM1 cells, with the remaining cells in culture being susceptible, parental PM1 T cells. To some cultures, approximately 10% irradiated, NFN-SX-r-HSAS-infected PM1 T cells were added. As all CAD-and CAD-R5-transduced cells express tNGFR, it is possible to follow the survival and expansion of these cells by flow cytometry and quantify changes over time. Moreover, the number of virally infected PM1 T cells can be determined by flow cytometry as well by using antibodies to cell surface mHSA produced during a productive NFN-SX-r-HSAS infection. Figure 4a Thus, it appears that tNGFR-positive cells isolated from HIV-1-infected cultures after 21 days and cultured for 6 additional days contained few infected cells. It should be noted that the p1% mHSA-positive CAD-R5 PM1 T cells obtained from the day 6 culture might indicate that a small number of tNGFR-positive cells were productively infected or that tNGFR-negative cells were carried along during magnetic bead separation. Alternatively, this observation could be owing to the uptake of the GPI-linked mHSA by uninfected, tNGFRpositive cells in the original 21-day cultures. To distinguish between the possibilities of continued infection or mHSA carryover, the CAD-R5 PM1 T-cell cultures after 27 days were maintained for an additional 5 weeks and evaluated by flow cytometry. The long-term cultured tNGFR-positive cells were found to be p1% mHSA 
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positive by flow cytometry (data not shown). These results suggest that if infected cells were present in the culture, they died off or were overgrown by non-infected cells over time, or that the mHSA reactivity was a carry over from the original isolation. Overall, our findings suggest that the majority of PM1 T cells expressing CCR5 intrabody, which survive, grow and expand during a 21-day culture in the presence of infected PM1 T cells, are mHSA negative and remain so when isolated from culture.
Primary T cells expressing CCR5 intrabody are protected from DC-mediated HIV-1 infection and enrich over time
Cell-to-cell contact, specifically between HIV-1-infected or viral-positive professional antigen-presenting cells and uninfected CD4 + T cells in lymph nodes and other immune privilege sites, termed the infectious immunological synapse, has been proposed to be a highly efficient and, most likely, a major physiological means of CD4 + T-cell infection. [20] [21] [22] [23] [24] As we have demonstrated, CAD-R5-transduced primary CD4 + T cells were refractory to infection by free virus. However, given the major role of DCs in HIV-1 T-cell infection, we considered it necessary to evaluate whether CAD-R5-transduced primary CD4
+ T cells are protected and expand when a stronger and more efficient HIV-1 challenge is mediated through viral presentation by DCs. To accomplish this goal, we used a modified version of the assays developed by Gummuluru et al. 22, 39 This tissue culture method relies on HIV-1-pulsed DCs to form an immune synapse with CD4 + T cells, allowing for a productive cell-to-cellmediated infection. 20, 24 Activated, primary CD4 + T cells were transduced with either the CAD or CAD-R5 vector at low MOI to achieve 20-30% transduction efficacy, cultured, rested, reactivated and equal numbers of CADor CAD-R5-transduced cells were then co-cultured with autologous, DCs that have been pulsed with R5-tropic SF-162. Figure 5 presents the results of the changes of tNGFR-positive cells for two independent studies. Flow cytometry analyses before DC introduction on day 0, and on days 6 and 9 post-dendritic co-culture demonstrated a significant amount of enrichment of the CAD-R5-transduced CD4 + T cells. In two independent experiments, CD4 + T cells transduced with the CAD-R5 vector enriched by 75 and 67%, respectively, by day 9. In contrast, T-cell cultures containing the CAD-transduced CD4 + T cells decreased 31 and 35% in tNGFR-positive cells. These results suggest that CAD-R5-transduced CD4 + T cells have a survival and/or growth advantage in the presence of an ongoing DC-mediated HIV-1 infection.
Discussion
Small-molecule chemokine receptor antagonists have the potential to disseminate throughout the patient to most immune compartments and disrupt HIV entry. 40, 41 In contrast, clinical gene delivery at the current time is limited in its ability to target most HIV susceptible cells in patients. 36 An underlying rationale for clinical use of anti-HIV gene delivery is that susceptible cells expressing the protective gene of interest will be refractory to viral infection, survive and enrich during an immunological response to HIV infection. Surprisingly, only a few anti-HIV gene delivery strategies have been evaluated for their ability to provide a survival and enrichment function in the presence of an ongoing HIV infection. 19, 42, 43 Our findings demonstrate that HIV-1 vector delivery of CCR5 intrabody genes to T-cell lines and primary CD4 + cells rendered them resistant to HIV-1 challenge, either from free or DC presented virus. Most importantly, CCR5 intrabody-expressing T cells have a competitive survival and growth advantage during ongoing HIV-1 viral spread in tissue culture.
The introduction of highly active anti-retroviral therapy has resulted in clinical management of HIV-1 infection and has changed the course of a fatal disease to one that is now a chronic condition. 44, 45 However, antiretroviral drug toxicity and the lack of patient compliance have given rise to drug-resistant viral mutations, viral progression and the urgent need for new anti-viral treatments. [46] [47] [48] [49] In this regard, CCR5 is an attractive target for therapeutic intervention to halt viral entry, as CCR5-dependent virus is associated with primary and early stages of infection, 6 and individuals with a homozygous mutation of CCR5 (D32) are resistant to R5-tropic HIV-1 infection. [7] [8] [9] [10] 50 Currently, there are a number of chemokine receptor antagonists under review. 40, 41, [51] [52] [53] An alternative therapeutic method for disrupting HIV entry is the use of gene delivery to provide a genetic means to alter expression or block the function of chemokine receptors, for example, intrabodies, ribozymes, intrakines, zinc-fingers or RNAi. [13] [14] [15] [16] 54 Our approach to disrupting CCR5 expression on the cell surface relies on cellular expression of a humanized intrabody targeting CCR5. 16 The CCR5 intrabody recog- 
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CH Swan et al nizes and binds the sequence YYTSEP in the first extracellular domain of CCR5 at low nM affinity. 55 The intrabody binding motif partially overlaps with the gp120 binding and fusion motif. [56] [57] [58] [59] [60] To further improve cellular efficacy of the intrabody, a KDEL endoplasmic retention signal has been included, which provides entrapment of newly synthesized and recycled CCR5 as well and maintains cellular compartmentalization of the CCR5 intrabody. 16, 25 As shown in Figure 1b and c, CCR5 levels are substantially reduced (X95%) in lymphocyte and myeloid cell lines and, most importantly, primary CD4 + T cells. Moreover, the CCR5 intrabody targeting effect is restricted to CCR5 as seen in the lack of CXCR4 disruption, Figure 1d , and protection to X4-tropic viruses, Figure 2c .
Direct HIV challenge experiments at relatively high input (MOI 1) provide evidence that humanized CCR5 intrabody expression from stable integration of the CAD-R5 vector in primary CD4
+ T cells was sufficient to disrupt CCR5 and prevent infection (Figure 2b) . Moreover, CCR5 intrabody expression in a small number of PM1 T cells allowed survival and enrichment over time in infected cultures, further confirming that potent cellto-cell viral spread to CCR5 intrabody-expressing cells was curtailed (Figure 4a ). Moreover, conformation that CAD-R5-positive T cells remained for the most part mHSA negative for 21 days while co-cultured with HIV-1-infected T cells further supports the notion that CCR5 levels were insufficient for viral entry (Figure 4b ). Recent studies by Cordelier et al. 18 using SV40 delivery of CCR5 intrabody genes to cell lines and primary monocytes were found to be susceptible to HIV infection despite showing substantial reduction in CCR5 expression. However, therapeutic efficacy could be achieved if a second SV40 vector containing a CCR5 ribozyme was cotransduced, thus suggesting that an additional genetic disruption mechanism was required to lower levels of cell surface CCR5 to some threshold, thereby abrogating infection. The concern of partial protection from viral infection has been noted for CCR5 disruption mechanisms when used individually to protect T cells, such as short hairpin RNA, ribozymes or intrabodies, when higher viral challenge amounts were used. 17, 18, 61 A possible explanation for the enhanced efficacy of the CCR5 intrabody in our studies could lie in the coupling of the KDEL sequence with a high-affinity intrabody. 16, 25 The use of the KDEL allows efficient intrabody trapping of both recycled and newly expressed receptor in the endoplasmic reticulum, thereby enhancing CCR5 loss at the cell surface.
An advantage of HIV-1-derived vectors is their ability to transduce both dividing and non-dividing cells such as resting T cells, DCs, macrophages and non-cycling hematopoietic stem cells (HSCs), thereby limiting problems associated with HSC culture, such as maturation and loss of stem cell potential. 62, 63 Our findings from CD34 + cell transplant studies in NOD/SCID-hu thy/liv mice suggest that CAD-R5 vector and CCR5 intrabody expression does not overtly alter T-cell development (Table 1) . Furthermore, intrabody expression is stable and remains functional for at least 8 weeks. These results are in accord with our observations that CAD-and CAD-R5-transduced primary and T-cell lines did not demonstrate discernable alterations in growth as compared to untransduced cells (data not shown). Additionally, we have observed long-term intrabody expression, without intrabody silencing or cellular alterations, in human B-and myeloid cell populations obtained from long-term repopulating cells in NOD/SCID mice transplanted with CAD and CAD-R5 vector-transduced CD34 + cells (KL Fischer and BE Torbett, unpublished studies, 2005). The use of intrabodies in other cell-based systems have not been reported to alter growth and development. [64] [65] [66] Although CCR5 intrabody expression is functional and limits the amount and duration of viral spread at the population level in CD4 + T cells isolated from the human thymus (Figure 3) , additional studies are required to determine the variability of CAD-R5-mediated protection provided to individual CD4 + T cells derived from transduced CD34 + progenitors. DCs are the pivotal antigen-presenting cells for induction of T-cell immunity to pathogens and recent evidence suggests that HIV-1 preferentially targets CD4 + T cells specific for HIV-1 antigens in infected individuals. 67 Additional evidence points to enhanced viral replication in DC-CD4 + T-cell clusters and the highly efficient ability of DCs to transfer virus to susceptible cells in the immunological synapse. [20] [21] [22] [23] [24] We found that CCR5 intrabody-expressing primary CD4 + T cells increase during co-culture with viral-pulsed DCs, as compared to reporter vector control CD4 + cells, which implies a competitive advantage for cells having reduced CCR5 expression ( Figure 5 ). The primary CD4 + T-cell enrichment results, when taken with the findings of the CCR5 intrabody protection in direct viral challenges, indicates that delivery of CCR5 intrabody genes allows survival and protection from robust viral challenges. These results further imply that we have achieved therapeutic efficacy in small numbers of CD4 + T cells in a population setting by decreasing the threshold of CCR5 available for viral entry. We propose that there may be an advantage to removing CCR5 from the cell surface via gene delivery, in contrast to using CCR5 small molecule antagonists or gene delivery methods that block CCR5 on the cell surface, to reduce the probability of selecting viral mutants that would continue to use CCR5 for viral entry in the presence of the antagonist. 68, 69 The consequence of reducing the level of CCR5, as to whether the CCR1 and CCR3 receptors will compensate for the loss of CCR5 in vivo, remain unknown. Furthermore, a report by Glass et al. 70 have determined that the CCR5 D32 deletion is significantly related to symptomatic and fatal consequence of West Nile virus infection. It is therefore necessary to examine the full spectrum of immunological defects that may arise by disrupting CCR5 in HSCs and T cells in large animal models.
In summary, our studies provide evidence that CCR5-mediated cell surface disruption by HIV vector expression of CCR5 intrabodies both protects and allows expansion of primary CD4 + T cells. Coupled with HIV vector delivery, intrabody targeting of chemokine receptors provides a powerful phenotypic disruption strategy possibly suitable for HIV-1 salvage therapy.
Materials and methods
Primary T and hematopoietic cells
Whole-blood samples were obtained from healthy donors under the auspices of the General Clinical Peripheral blood lymphocytes (PBLs) were isolated from blood via density-gradient centrifugation using Ficoll-Hypaque Plus (Amersham Biosciences, Sweden). CD8 + cells were removed by positive selection using anti-CD8
+ magnetic microbeads (Stem Cell Technologies, Canada) and a Miltenyi magnetic column (Miltenyi Biotech, Germany) as per the manufacturer's protocol. Purity was assessed by flow cytometry with the appropriate chromophore-labeled antibody reagents. CD34 + fetal liver cells were selected using anti-CD34
+ magnetic microbeads (Stem Cell, Canada) and isolated on a Miltenyi magnetic column (Miltenyi Biotech, Germany) as described. 62 Cell culture 293 T cells (a kind gift of CellGenesys, San Francisco, CA, USA) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and antibiotics (GIBCO/BRL, Invitrogen, Carlsbad, CA, USA), and maintained in a humidified 371C incubator containing 10% CO 2 .
PM1 71 and THP-1 72 cells were cultured in RPMI 1640 containing 10% FBS, 10mM HEPES and antibiotics (cRPMI), and passaged every 3 days. All cell lines were maintained in a 371C humidified incubator containing 5% CO 2 .
For primary CD4 + T-cell studies, 1 Â 10 6 CD8 + -depleted PBLs/ml were cultured in cRPMI and activated with 5 mg/ml PHA and 20 U/ml interleukin (IL)-2. After 2 days of culture, cells were washed and cultured in cRPMI with 20 U/ml IL-2. Cells were reactivated on day 9 of culture with 5 mg/ml PHA and 20 U/ml IL-2 for 2 days. After 2 days of reactivation, cells were cultured in cRPMI with 20 U/ml IL-2. All cultures were maintained in a 371C humidified incubator containing 5% CO 2 . CD34 + cells isolated from the fetal liver were cultured at 4.5 Â 10 6 cells/ml in Iscove's modified Dulbecco's medium, 10% bovine serum albumin, insulin and transferrin (BIT) (Stem Cell, Canada), 1% FBS, 50 ng/ml thrombopoietin, 50 ng/ml stem cell factor, 20 ng/ml IL-6, 100 ng/ml FLT-3, antibiotics and 1 mM b-mercaptoethanol for vector transduction purposes. All cultures were maintained in a 371C humidified incubator containing 5% CO 2 .
HIV-1 production
The R5-tropic NFN-SX-r-HSAS and X4-tropic NL-r-HSAS mHSA reporter viruses were prepared by transfection of the molecular clone into 293 T cells to generate infectious virus, which was then amplified by infecting the PM1 T-cell line or primary cells. 16, 29 NHL-r-HSAS is based on NL4-3 with the murine heat-stable antigen in place of vpr.
16,29 NFN-SX-r-HSAS use the env of JR-FL, which replaces the endogenous env of NHL-r-HSAS. 16, 29 The R5-tropic SF-162 and the X4-tropic LAI viruses were obtained from viral supernatant infection of PHA (5mg/ ml)-activated primary CD8
+ -depleted PBL cultures.
Tissue culture supernatant was collected 7-9 days postculture and tested for p24 concentration, by the University of California, San Diego, CA, USA, CFAR, using the antigen capture ELISA test (Beckman Coulter, Fullerton, CA, USA) according to the manufacturer's instructions.
Generation of the CAD and CAD-R5 HIV-1 SIN vectors
To ensure long-term expression in hematopoietic cells, we have generated an HIV-1 SIN vector, which incorporated a number of unique elements (Figure 1a , CAD series vector). A myeloproliferative sarcoma virus longterminal repeat (LTR)-negative control region deleted (MND, myeloproliferative sarcoma virus LTR-negative control region deleted) was selected as the internal promoter based on the demonstration of high expression of selected genes (unpublished data and Halene et al. 73 and Aviles Mendoza et al.
74
) and the presence of altered LTR elements that preclude methylation, which supported long-term expression in mouse long-term hematopoietic progenitors upon repeated passage. 62, 75 Lastly, we have also included the 800 bp 3 0 interferon (IFN)-bscaffold attachment region (SAR) element 3 0 of all genes. A SAR element may be critical for keeping the vector transcriptionally active during the resting state of a cell, after cell expansion and for inhibiting methylation. [76] [77] [78] When present in an MLV vector, a SAR element has been shown to increase expression in both resting and activated human T and myeloid cells and provides protection from silencing. [76] [77] [78] A complete description of the CAD vector cloning strategy is available upon request. Briefly, the CAD control vector was assembled by standard cloning techniques from the following elements: vector backbone was derived from CS-PRE, a derivative of HIV-CS (kind gift of H Miyoshi, 75 University of Tsukuba, Japan), which has unique BamHI, SacII, EcoRI, XbaI, HpaI and XhoI sites upstream of the post-translational regulatory element. 79 The MND LTR was cloned from the MND-HSPSV-EGFP plasmid (kind gift of Don Kohn, USC School of Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA) and cloned into the BamHI site. The 178-bp polypurine tract-central terminating sequence (cPPT-CTS) BamH1/ Sma1 fragment was amplified from HIV-1 molecular clone R8. 80 The cellular internal ribosomal entry site (cIRES) and tNGFR (cIRES-tNGFR) BamHI/ClaI fragment were cloned from plasmid pSK+100eIF4 (kind gift of Gabor Veres, SyStemix, Palo Alto, CA, USA). The 800 bp 3 0 SAR element was cloned from plasmid pCL, introducing Xba1/Hpa1 sites. 81 The humanized CCR5 intrabody, ST6/34, was generated and cloned as described previously. 55 The CAD-R5 CCR5 intrabody vector was constructed from CAD by replacing the BamHI MND promoter fragment with an MND promoter and the intrabody fragment.
CAD and CAD-R5 virion particles were produced by transient calcium phosphate co-transfection as described. 62, 75 Briefly, the CAD and CAD-R5 transfer vectors (10 mg/dish) were co-transfected with the packaging construct pMDLg/pRRE (6.5 mg), pRSV-rev (2.5 mg) and a vesicular stomatitis virus-G expression construct (3.5 mg) into 2 Â 10 6 293 T cells. 62 Tissue culture supernatant was harvested 24 and 48 h later and concentrated 1000-fold by ultracentrifugation. MOI was calculated based on serial titers using 293 T cells in triplicate as an CCR5 intrabody-mediated protection and enrichment of T cells during HIV-1 infection CH Swan et al indicator line, as we have previously described in Miyoshi H et al.
62,75
HIV-1 vector transduction PM1 and THP-1 cells were transduced in the presence of 8 mg/ml polybrene or protamine sulfate, respectively, in cRPMI with selected MOI of 1 CAD or CAD-R5 vector overnight, washed and maintained as described above. CD8 + -depleted PBLs were transduced with the CAD or CAD-R5 vector at an MOI of 50 on day 2 of culture for 8 h in the presence of 8 mg/ml polybrene. Cells were washed and cultured in complete RPMI with 20 U/ml IL-2. Seven days post-transduction, tNGFR-positive cells were isolated via immunomagnetic bead isolation using NGFR-phycoerythrin (PE)-conjugated antibody (BD Biosciences: Pharmingen, San Diego, CA, USA) and a-PE dextran/a-dextran magnetic beads (Stem Cell Technologies, Canada) using a Miltenyi magnetic column (Miltenyi Biotec, Germany). Isolated cells were reactivated with 5 mg/ml PHA and 20 U/ml IL-2 for 2 days, and then cultured in cRPMI with 20 U/ml IL-2. CD34 + fetal liver stem cells were transduced with the CAD or CAD-R5 vector (MOI 25) on days 2 and 3 of culture overnight in the presence of 3 mg/ml polybrene. Cells were washed after each transduction and maintained as described above.
HIV-1 infection
PM1 cells were infected with R5-tropic NFN-SX-r-HSAS HIV-1 and lethally irradiated and used to challenge the PM1 T-cell line. As a CCR5 intrabody specificity control, PM1 cells were infected with X4-tropic NL-r-HSAS at an MOI of 0.1. Primary T cells were infected with R5-tropic SF-162 (MOI 1) or X4-tropic LAI (MOI 0.1) HIV-1 for 3-6 hours in the presence of 8 mg/ml polybrene on day 11 of culture, cells were washed and re-cultured for the desired time. Tissue culture supernatant was collected during various time points for HIV-1 p24 determination and p24 was determined, using triple or quadruplicate samples, by the University of California, San Diego, CA, USA, CFAR, using the antigen capture ELISA test (Beckman Coulter) according to the manufacturer's instructions. All p24 amounts are presented as mean7s.d., where appropriate. In many cases, the variation was less than 10% of the mean.
Flow cytometry analysis
CAD and CAD-R5 tNGFR reporter gene expression was detected by flow cytometry analysis on cells stained with the PE-labeled antibody C40-1457 (BD Biosciences: Pharmingen, San Diego, CA, USA) to NGFR. The fluorescein isothiocyanate (FITC)-labeled version was a kind gift of Gabor Veres, SyStemix (Palo Alto, CA, USA). NFN-SX-r-HSAS and NL-r-HSAS HIV reporter gene expression on the cell surface was detected by the FITC-labeled antibody H1/69 to mHSA (eBioscience, San Diego, CA, USA). CCR5 expression on primary T cells was detected by indirect staining with 2D7 antibody (BD Biosciences: Pharmingen, San Diego, CA, USA) followed by PE-labeled donkey anti-mouse serum (Jackson Immunoresearch, West Grove, PA, USA) or directly using PE-labeled 2D7 antibody (BD Biosciences: Pharmingen, San Diego, CA, USA). CCR5 expression on THP-1 cells was detected by PE-labeled 2D7 antibody. CXCR4 expression on primary T cells was detected by PE-or FITC-labeled 12G5 antibody (BD Biosciences: Pharmingen, San Diego, CA, USA). Cells were analyzed on Becton Dickinson FACScan using CELLQUEST software.
NOD/SCID-hu thy/liv mouse model NOD/SCID mice were bred and treated with antibiotics in accordance with the animal care and use committee at The Scripps Research Institute (ARC no. 06JAN02). Mice (7-8 weeks old) were placed under anesthesia (methoxyflurane and pentobarbitol) during the surgical procedure. Human fetal liver-thymus-liver tissue sections (B3 mm 3 ) were placed under the left kidney capsule. Two months post-thymus establishment, mice were irradiated with 325 rads. One day post-irradiation, mice were placed under anesthesia as described above and 2.5 Â 10 5 CD34 + HLA-mismatched fetal liver cells (mock, CAD-or CAD-R5-transduced cells) were injected into the human thymus. Six weeks post-CD34 + injection, mice were killed and thymi were harvested for analysis and prepared into a single-cell suspension for flow cytometry analysis and cell culture.
Two-color flow cytometry analysis was performed on thymocytes stained with anti-human antibodies, CD4
+ -FITC and CD8 + -PE (Beckman Coulter, Fullerton, CA, USA), HLA-A2 FITC, CD8
+ -FITC and NGFR-PE (BD Biosciences, Pharmingen, San Diego, CA, USA). The CAD and CAD-R5 thymocyte groups were enriched for tNGFR-positive cells via immunomagnetic isolation as described above. Cultures were established with 80% tNGFR-positive thymocytes and 20% non-transduced thymocytes and activated with 5 mg/ml PHA and 20 U/ml IL-2 for 3 days in cRPMI, washed and cultured in cRPMI with 20 U/ml IL-2. On day 3 of culture, cells were infected with R5-tropic SF-162 at an MOI of 1 in the presence of 8 mg/ml polybrene, washed and re-cultured for the desired time. Tissue culture supernatant was collected during various time points for HIV-1 p24 concentration and prepared as described above.
Primary CD4 + T-cell enrichment assay
The primary T-cell enrichment assay is a modification of the rapid-turnover assay developed and described by Gummuluru et al. 22, 39 CD8 + T cells were isolated and depleted as described previously. Immature DCs were enriched from an autologous donor via immunomagnetic cell sorting using anti-CD14 + microbeads (Stem Cell Technologies, Canada) and isolated on a Miltenyi magnetic column (Miltenyi Biotech, Germany). CD4 + T cells were activated, cultured and transduced with the CAD and CAD-R5 vector as described previously. DCs were cultured at 1 Â 10 6 cells/ml in cRPMI plus 500 U/ ml IL-4 and 800 U/ml granulocyte-macrophage colonystimulating factor (GM-CSF) for 7 days. On day 7 of culture, DCs were pulsed with 500 ng p24 SF-162 viral supernatant for 2-6 h and washed thoroughly three times with phosphate-buffered saline. The HIV-1-exposed DCs were then co-cultured with the CAD-or CAD-R5-transduced CD4 + T cells at a ratio of 1:10 with tNGFR-positive transduced cells representing 20-30% of the total cell population. CD4 + T cells were reactivated for 2 days with 5 mg/ml PHA and 20 U/ml IL-2 before co-culturing with DCs. CD4 + T cells and DCs were cocultured in cRPMI with 20 U/ml IL-2, 500 U/ml IL-4 and 800 U/ml GM-CSF, and media were changed every 3 CCR5 intrabody-mediated protection and enrichment of T cells during HIV-1 infection CH Swan et al days. Cells were stained with NGFR-PE before the introduction of DCs on day 0, and on days 6 and 9 post co-culture for flow cytometry analysis. Enrichment was determined by the percentage of tNGFR-positive cells.
